399 related articles for article (PubMed ID: 30398482)
1. An update of treatments of hepatocellular carcinoma in patients refractory to sorafenib.
Ielasi L; Sansone V; Granito A; Benevento F; De Lorenzo S; Tovoli F
Drugs Today (Barc); 2018 Oct; 54(10):615-627. PubMed ID: 30398482
[TBL] [Abstract][Full Text] [Related]
2. Second-line treatment of hepatocellular carcinoma after sorafenib: Characterizing treatments used over the past 10 years and real-world eligibility for cabozantinib, regorafenib, and ramucirumab.
Fung AS; Tam VC; Meyers DE; Sim HW; Knox JJ; Zaborska V; Davies J; Ko YJ; Batuyong E; Samawi H; Cheung WY; Lee-Ying R
Cancer Med; 2020 Jul; 9(13):4640-4647. PubMed ID: 32378799
[TBL] [Abstract][Full Text] [Related]
3. Comparative Efficacy of Cabozantinib and Regorafenib for Advanced Hepatocellular Carcinoma.
Kelley RK; Mollon P; Blanc JF; Daniele B; Yau T; Cheng AL; Valcheva V; Marteau F; Guerra I; Abou-Alfa GK
Adv Ther; 2020 Jun; 37(6):2678-2695. PubMed ID: 32424805
[TBL] [Abstract][Full Text] [Related]
4. Regorafenib versus cabozantinb as second-line treatment after sorafenib for unresectable hepatocellular carcinoma: matching-adjusted indirect comparison analysis.
Casadei-Gardini A; Rimassa L; Rimini M; Yoo C; Ryoo BY; Lonardi S; Masi G; Kim HD; Vivaldi C; Ryu MH; Rizzato MD; Salani F; Bang Y; Pellino A; Catanese S; Burgio V; Cascinu S; Cucchetti A
J Cancer Res Clin Oncol; 2021 Dec; 147(12):3665-3671. PubMed ID: 33745079
[TBL] [Abstract][Full Text] [Related]
5. Regorafenib for the treatment of hepatocellular carcinoma.
Tovoli F; Granito A; De Lorenzo S; Bolondi L
Drugs Today (Barc); 2018 Jan; 54(1):5-13. PubMed ID: 29569657
[TBL] [Abstract][Full Text] [Related]
6. Review article: systemic treatment of hepatocellular carcinoma.
Pinter M; Peck-Radosavljevic M
Aliment Pharmacol Ther; 2018 Sep; 48(6):598-609. PubMed ID: 30039640
[TBL] [Abstract][Full Text] [Related]
7. Cabozantinib in patients with hepatocellular carcinoma failing previous treatment with sorafenib.
Personeni N; Pressiani T; Rimassa L
Future Oncol; 2019 Jul; 15(21):2449-2462. PubMed ID: 31204849
[TBL] [Abstract][Full Text] [Related]
8. Molecular therapies for HCC: Looking outside the box.
Faivre S; Rimassa L; Finn RS
J Hepatol; 2020 Feb; 72(2):342-352. PubMed ID: 31954496
[TBL] [Abstract][Full Text] [Related]
9. Molecular targeted and immune checkpoint therapy for advanced hepatocellular carcinoma.
Liu Z; Lin Y; Zhang J; Zhang Y; Li Y; Liu Z; Li Q; Luo M; Liang R; Ye J
J Exp Clin Cancer Res; 2019 Nov; 38(1):447. PubMed ID: 31684985
[TBL] [Abstract][Full Text] [Related]
10. Comparative efficacy and safety for second-line treatment with ramucirumab, regorafenib, and cabozantinib in patients with advanced hepatocellular carcinoma progressed on sorafenib treatment: A network meta-analysis.
Chen J; Wang J; Xie F
Medicine (Baltimore); 2021 Sep; 100(38):e27013. PubMed ID: 34559096
[TBL] [Abstract][Full Text] [Related]
11. Immunomodulatory Effects of Current Targeted Therapies on Hepatocellular Carcinoma: Implication for the Future of Immunotherapy.
Lin YY; Tan CT; Chen CW; Ou DL; Cheng AL; Hsu C
Semin Liver Dis; 2018 Nov; 38(4):379-388. PubMed ID: 30357775
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of annexin A3 blockade in sensitizing hepatocellular carcinoma to sorafenib and regorafenib.
Tong M; Che N; Zhou L; Luk ST; Kau PW; Chai S; Ngan ES; Lo CM; Man K; Ding J; Lee TK; Ma S
J Hepatol; 2018 Oct; 69(4):826-839. PubMed ID: 29885413
[TBL] [Abstract][Full Text] [Related]
13. Optimizing Survival and the Changing Landscape of Targeted Therapy for Intermediate and Advanced Hepatocellular Carcinoma: A Systematic Review.
Lim H; Ramjeesingh R; Liu D; Tam VC; Knox JJ; Card PB; Meyers BM
J Natl Cancer Inst; 2021 Feb; 113(2):123-136. PubMed ID: 32898239
[TBL] [Abstract][Full Text] [Related]
14. Review article: new therapeutic interventions for advanced hepatocellular carcinoma.
Bangaru S; Marrero JA; Singal AG
Aliment Pharmacol Ther; 2020 Jan; 51(1):78-89. PubMed ID: 31747082
[TBL] [Abstract][Full Text] [Related]
15. Regorafenib: a promising treatment for hepatocellular carcinoma.
Cerrito L; Ponziani FR; Garcovich M; Tortora A; Annicchiarico BE; Pompili M; Siciliano M; Gasbarrini A
Expert Opin Pharmacother; 2018 Dec; 19(17):1941-1948. PubMed ID: 30345837
[No Abstract] [Full Text] [Related]
16. Regorafenib for the treatment of unresectable hepatocellular carcinoma.
Rimassa L; Pressiani T; Personeni N; Santoro A
Expert Rev Anticancer Ther; 2017 Jul; 17(7):567-576. PubMed ID: 28580808
[TBL] [Abstract][Full Text] [Related]
17. Molecular therapies and precision medicine for hepatocellular carcinoma.
Llovet JM; Montal R; Sia D; Finn RS
Nat Rev Clin Oncol; 2018 Oct; 15(10):599-616. PubMed ID: 30061739
[TBL] [Abstract][Full Text] [Related]
18. Pharmacogenetics of the systemic treatment in advanced hepatocellular carcinoma.
De Mattia E; Cecchin E; Guardascione M; Foltran L; Di Raimo T; Angelini F; D'Andrea M; Toffoli G
World J Gastroenterol; 2019 Aug; 25(29):3870-3896. PubMed ID: 31413525
[TBL] [Abstract][Full Text] [Related]
19. [New Systemic Therapies for Advanced Hepatocellular Carcinoma].
Kim DY
Korean J Gastroenterol; 2019 Jan; 73(1):10-15. PubMed ID: 30690953
[TBL] [Abstract][Full Text] [Related]
20. Systemic therapy for intermediate and advanced hepatocellular carcinoma: Sorafenib and beyond.
Raoul JL; Kudo M; Finn RS; Edeline J; Reig M; Galle PR
Cancer Treat Rev; 2018 Jul; 68():16-24. PubMed ID: 29783126
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
